Gilead Expands Low-Cost HIV Drug Program

Xconomy San Francisco — 

Gilead Sciences (NASDAQ: GILD), the world’s largest maker of HIV drugs, said today it has expanded its global access program to offer HIV/AIDS drugs at low prices in poor countries. The Foster City, CA-based company said four Indian partners and the Medicines Patent Pool Foundation will get access to the experimental drug elvitegravir, the experimental “Quad” that combines four antiviral meds into a single daily pill, and an antiretroviral boosting agent. Partners will have the rights to sell generic versions of the new Gilead medicines, if they are approved by regulators, the company said.

By posting a comment, you agree to our terms and conditions.

Comments are closed.